Verosudil
CAS No. 1414854-42-4
Verosudil( AR-12286 )
Catalog No. M11719 CAS No. 1414854-42-4
Verosudil (AR-12286) is a potent ROCK inhibitor (Ki=0.2 nM) that effectively lowers intraocular pressure (IOP) in animal models and human subjects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 1152 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVerosudil
-
NoteResearch use only, not for human use.
-
Brief DescriptionVerosudil (AR-12286) is a potent ROCK inhibitor (Ki=0.2 nM) that effectively lowers intraocular pressure (IOP) in animal models and human subjects.
-
DescriptionVerosudil (AR-12286) is a potent ROCK inhibitor (Ki=0.2 nM) that effectively lowers intraocular pressure (IOP) in animal models and human subjects Other Indication Phase 2 Discontinued.
-
In Vitro——
-
In Vivo——
-
SynonymsAR-12286
-
PathwayCell Cycle/DNA Damage
-
TargetROCK
-
RecptorROCK
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number1414854-42-4
-
Formula Weight327.402
-
Molecular FormulaC17H17N3O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 16.67 mg/mL (50.92 mM)
-
SMILESCN(C)C(C1=CSC=C1)C(=O)NC2=CC3=C(C=C2)C(=O)NC=C3
-
Chemical Name2-(dimethylamino)-N-(1-oxo- 1,2-dihydroisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sturdivant JM, et al. Bioorg Med Chem Lett. 2016 May 15;26(10):2475-80.
2. Kopczynski C, et al. Br J Ophthalmol. 2013 May;97(5):567-72.
3. Williams RD, et al. Am J Ophthalmol. 2011 Nov;152(5):834-41.e1.
molnova catalog
related products
-
ROCK2-IN-2
ROCK2-IN-2 is a selective inhibitor of ROCK2 (IC50 of <1 μM).
-
CRT0066854 hydrochlo...
CRT0066854 hydrochloride is an effective selective atypical PKCs inhibitor.
-
Cucurbitacin A
Cucurbitacin I, cytotoxic triterpenoid sterols isolated from plants, elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-Kinase.
Cart
sales@molnova.com